Navigation Links
InterMune Announces Four Oral Presentations on Pirfenidone and IPF at the Annual Congress of the European Respiratory Society (ERS)
Date:9/13/2010

  • 10:00 a.m. -- Percent predicted forced vital capacity is a reliable, valid, and responsive measure of clinical status in patients with idiopathic pulmonary fibrosis (Ron du Bois, M.D.)

  • About Pirfenidone

    InterMune has submitted a Marketing Authorization Application (MAA) seeking approval of pirfenidone for the treatment of idiopathic pulmonary fibrosis (IPF) in adults, which was validated by the European Medicines Agency (EMA) effective March 24, 2010. Validation of the MAA by the EMA indicates that the application is complete and that the review process has begun.

    IPF is a rare and fatal lung disease that affects approximately 200,000 people in the United States and Europe combined. If approved by the EMA, pirfenidone would be the first medication to be made available to IPF patients in the European Union. Pirfenidone has been granted Orphan Drug designation in Europe.

    Preclinical and in-vitro evidence has shown that pirfenidone has both anti-fibrotic and anti-inflammatory effects. In February 2009, InterMune announced the results of the company's two global Phase 3 clinical trials evaluating pirfenidone for the treatment of IPF, known as the CAPACITY trials. Prior to the CAPACITY results, Shionogi & Co. Ltd (Shionogi) had presented data from a Phase 3 study conducted in Japan which demonstrated that pirfenidone reduced the decline in lung function and improved progression-free survival in patients with IPF. In this clinical study, pirfenidone was safe and generally well-tolerated, with the most frequent side effects reported being photosensitivity rash and gastrointestinal symptoms. In October of 2008, pirfenidone was approved for use in IPF patients in Japan and is marketed as Pirespa® by Shionogi in that country.

    About InterMune

    InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology.
    '/>"/>

    SOURCE InterMune, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related medicine technology :

    1. InterMune to Release Second Quarter Financial Results on July 27
    2. InterMune Announces Conference Call and Webcast to Discuss Outcome of FDA Advisory Committee
    3. FDA Advisory Committee Recommends Approval of InterMunes Esbriet(R) (pirfenidone) for Idiopathic Pulmonary Fibrosis
    4. InterMune Announces Posting of Briefing Documents for FDA Advisory Committee Meeting on Pirfenidone
    5. InterMune Reports Fourth Quarter and Full Year 2009 Financial Results and Business Highlights
    6. InterMune to Participate in Pulmonary-Allergy Drugs Advisory Committee Meeting on March 9, 2010
    7. InterMune to Present at Deutsche Bank Biotech Confab
    8. InterMune Reports Third Quarter 2009 Financial Results and Business Highlights
    9. InterMune Announces Submission of NDA for Pirfenidone for the Treatment of Patients with IPF
    10. InterMune to Present at JMP Securities Conference
    11. InterMune Reports Presentation of Triple Combination Study of ITMN-191 at European Association for the Study of the Liver (EASL)
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/23/2015)... 23, 2015 Gem Pharmaceuticals announced today that the ... into the Company,s Phase 2 clinical trial.  This open-label ... lead compound, GPX-150 (an investigational medication), in approximately 30 ... Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
    (Date:1/22/2015)... BOULDER, Colo. , Jan. 22, 2015  BiOptix is ... Klakamp as Vice President of Chemistry and Biochemistry. Scott ... Takeda Pharmaceuticals, AstraZeneca Pharmaceuticals, and Amgen throughout the course ... and development. "Scott is a nationally recognized ...
    (Date:1/22/2015)... , Jan. 22, 2015  Amgen (NASDAQ: AMGN ) today ... 2014 financial results on Tuesday, Jan. 27, 2015, after the close ... a conference call with the investment community at 2 p.m. PT. ... Bradway , chairman and chief executive officer, and other members of ...
    Breaking Medicine Technology:Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2Amgen Announces Webcast of 2014 Fourth Quarter and Full Year Financial Results 2
    ... In Follow-up Period -, EXTON, Pa., Jan. ... injections have been completed in the pivotal,Phase III ... Therapy(TM) for the treatment of,nasolabial folds, or wrinkles ... follow-up period of the study., Isolagen also ...
    ... CLINICAL TRIAL RESULTS PUBLISHED IN THE JOURNAL OF ... 14 BioForm Medical,Inc. (Nasdaq: BFRM ) ... randomized, blinded comparative study of nasolabial fold,treatments reporting ... more effective than Restylane(R), the leading dermal filler,on ...
    Cached Medicine Technology:Isolagen Inc. Completes Injections of Isolagen Therapy(TM) in Phase III Wrinkle and Phase II Full Face Studies 2RADIESSE More Effective Than Restylane As Reported In a 60-Patient Clinical Trial 2RADIESSE More Effective Than Restylane As Reported In a 60-Patient Clinical Trial 3RADIESSE More Effective Than Restylane As Reported In a 60-Patient Clinical Trial 4
    (Date:1/22/2015)... York, New York (PRWEB) January 22, 2015 ... http://www.vaginalmeshlawsuit2015.com/ ) in the U.S. District Court, Southern District of ... C.R. Bard, Inc. in that proceeding’s first bellwether trial. In ... request for a new trial after finding that C.R. Bard ...
    (Date:1/22/2015)... 20 years, Dr. David Cruz of Cruz Chiropractic Care ... about every type of injury that can result from car accidents ... years, the team at Doctors on Liens has been ... With the combined breadth of experience between the two, ...
    (Date:1/22/2015)... Recently, Weddingshe.com has added many trendy Champagne wedding ... revenues in the past three years. Today, the business announces ... According to the sales manager of the company, this is ... 2015. This point can be reflected on the discounted wedding ...
    (Date:1/22/2015)... January 22, 2015 As interest in the ... care gains momentum worldwide, Rev. Eric J. Hall , ... Network (HCCN), will be the keynote speaker on January ... Israel’s public health system. , The conference, “Hope and Resilience: ...
    (Date:1/22/2015)... 2015 State Forestry Institute of Mecklenburg-Vorpommern ... with support from GEOSYSTEMS, a dedicated Hexagon Geospatial and ... leverage Hexagon Geospatial’s ERDAS APOLLO for cataloging, ... as point clouds and documents. This effort will enable ...
    Breaking Medicine News(10 mins):Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 2Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 3
    ... Iridoids and Other ... ... (TNI) today set itself apart from the superfruits of the world yet again as modern ... plant that enhances the overall ability of the body to adapt to stress. Noni assists ...
    ... ... Kidney Diseases recommends capsaicin as an effective skin care regimen to help relieve itching associated ... be extremely hot. Now there,s a new skin spray made with the essence of hot ... ...
    ... ... be a simple matter of getting information about coverage that,s already available ... making concerted efforts to direct the uninsured to coverage, efforts by ordinary ... Charles Smith-Dewey, founder of one of the Web,s most respect health insurance ...
    ... ... opportunity for educational institutes to discuss their security requirements and compare their current Digital ... , ... (PRWEB) March 4, 2010 -- GlobalSign Inc ( www.globalsign.com ), one of the longest ...
    ... found that using high-resolution CT-scans to screen for lymphangioleiomyomatosis, or ... who come to the emergency room for the first time ... online ahead of print publication in the American Thoracic Society,s ... Pulmonary LAM is a rare but serious lung ...
    ... , ... help consumers keep track of their calories by scanning the barcodes on food items has gone ... ... who want to keep track of their daily nutritional intake by scanning the barcodes of items ...
    Cached Medicine News:Health News:Tahitian Noni Bioactive Beverages™ Are Adaptogenic 2Health News:Hot Pepper Itch Remedy Targets Kidney Disease Patients Suffering From Chronic Pruritus 2Health News:Consumer Health Insurance Site Founder: Health Reform or No Health Reform, Americans Can Help Reduce Rolls of the Uninsured 2Health News:Consumer Health Insurance Site Founder: Health Reform or No Health Reform, Americans Can Help Reduce Rolls of the Uninsured 3Health News:Consumer Health Insurance Site Founder: Health Reform or No Health Reform, Americans Can Help Reduce Rolls of the Uninsured 4Health News:Consumer Health Insurance Site Founder: Health Reform or No Health Reform, Americans Can Help Reduce Rolls of the Uninsured 5Health News:GlobalSign to Demonstrate Online Security Solutions to Educational Institutes at NERCOMP Conference 2Health News:GlobalSign to Demonstrate Online Security Solutions to Educational Institutes at NERCOMP Conference 3Health News:GlobalSign to Demonstrate Online Security Solutions to Educational Institutes at NERCOMP Conference 4Health News:GlobalSign to Demonstrate Online Security Solutions to Educational Institutes at NERCOMP Conference 5Health News:CT-scan screening for LAM in women with collapsed lung is cost-effective 2Health News:CT-scan screening for LAM in women with collapsed lung is cost-effective 3Health News:Barcode Joins the Battle of the Bulge in New iPhone App 2
    Malaria ( P. Falciparum ) Whole Blood Strip / Cassette...
    DiaMed OptiMAL-IT is an immuno-chromatographic test, using monoclonal antibodies against the metabolic enzyme pLDH (parasite lactate dehydrogenase) of Plasmodium spp. These Mabs are classified in t...
    Core Malaria Pf is a rapid self performing, qualitative, two site sandwich immunoassay for the determination of P. falciparum specific histidine rich protein 2 (Pf HRP-2) in whole blood samples...
    Ultraview SL 3800...
    Medicine Products: